This site is intended for US Healthcare Professionals.
COVID-19: Letter from Sun Pharmaceutical Industries
YONSA® is the first and only micronized abiraterone acetate formulation approved by the FDA, when used in combination with methylprednisolone. The advanced technology used in the formulation of YONSA® reduces abiraterone acetate particle size down to 200 to 800 nanometers in diameter1,2
SAFETY PROFILE
The most common adverse drug reactions (≥10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection, and contusion.
Proprietary YONSA®
micronization provides:
No food restrictions1,3
YONSA® gives patients the flexibility to take it with or without foodIncreased absorption1,2
Because a greater part of the active drug is getting absorbed, YONSA® is given as a 500 mg dose (four 125 mg tablets) taken once daily in combination with 4 mg methylprednisolone twice dailySimilar bioavailability2
YONSA®, in combination with 4 mg methylprednisolone, provides similar bioavailability to 1000 mg of abiraterone acetate with corticosteroid at a 500 mg dose.

TRICARE Network
Providers:
Learn more about
our exclusive
partnership with
the Department
of Defense.
WARNINGS AND PRECAUTIONS
Hypertension, Hypokalemia, and Fluid Retention Due to Mineralocorticoid Excess: YONSA® may cause hypertension, hypokalemia, and fluid retention due to increased mineralocorticoid levels resulting from CYP17 inhibition. Monitor patients at least once a month. Control hypertension and correct hypokalemia before and during treatment with YONSA®.
Learn about the
benefits of
micronization
benefits of
micronization
Learn how your
pharmacy can order
YONSA® today
pharmacy can order
YONSA® today
YONSA® is the first and only micronized formulation of abiraterone acetate1
Watch the video to learn how micronization affects the absorption of abiraterone acetate.

Micronization increases the particle’s surface area and enables more rapid dissolution and absorption; this results in2:
- A 500 mg dose (four 125 mg tablets plus two 4 mg methylprednisolone)1

Download to learn more about YONSA® and its benefits
DOWNLOAD